Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05191017 Withdrawn - Prostate Cancer Clinical Trials

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Start date: September 2022
Phase: Phase 1/Phase 2
Study type: Interventional

NUV-422-04 is an open-label Phase 1b/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with enzalutamide. The study population is comprised of adults with mCRPC. Patients will self-administer NUV-422 and 160 mg enzalutamide orally in 28-day cycles. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.

NCT ID: NCT05177276 Withdrawn - Clinical trials for Solid Tumor Malignancy

Selinexor Combination Ph 1 Study

Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of selinexor (KPT-330) in combination with Irinotecan in patients with solid tumors. A secondary purpose is to evaluate the pharmacokinetics (PK) of selinexor with irinotecan.

NCT ID: NCT05169151 Withdrawn - Sarcoma Clinical Trials

Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study

Start date: February 17, 2022
Phase:
Study type: Observational

This study attempts to learn more about the activity levels of adolescent and young adult (AYA) cancer patients or survivors at risk for cardiovascular morbidity and frailty by using a smartphone application called Beiwe. Collecting activity level data on AYA cancer patients or survivors may help patients achieve better quality of life.

NCT ID: NCT05165849 Withdrawn - Solid Tumor Clinical Trials

A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

Start date: April 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.

NCT ID: NCT05099536 Withdrawn - Solid Tumor, Adult Clinical Trials

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Start date: February 24, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.

NCT ID: NCT05071846 Withdrawn - Solid Tumor, Adult Clinical Trials

MVX-ONCO-2 in Advanced Solid Tumors

Start date: September 2022
Phase: Phase 1
Study type: Interventional

MVX-ONCO-2 is a patient-specific, cell-based, active immunotherapy where the participant's immune response to their own tumor cells is stimulated and/or increased. MVX-ONCO-2 is composed of a cell suspension of irradiated autologous tumor cells and two capsules loaded with allogenic genetically modified cells releasing an immunomodulator, granulocyte-macrophage colony stimulating factor (GM-CSF). MVX-ONCO-2 is an evolution of MVX-ONCO-1, which was approved for clinical investigation under the same category in a phase I and a phase II clinical trials. The objectives of the trial are to investigate the safety, tolerability and signals of efficacy of MVX-ONCO-2 in participants with advanced solid tumors.

NCT ID: NCT05060653 Withdrawn - Surgery Clinical Trials

Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases

BLEND-II
Start date: October 2022
Phase: N/A
Study type: Interventional

The aim of this study is to assess pain response after combining stereotactic body radiotherapy (SBRT) and pedicle screw fixation in a 48-hour window for the treatment of painful unstable metastases of the thoracic and/or lumbar spine.

NCT ID: NCT05060276 Withdrawn - Solid Tumor, Adult Clinical Trials

Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.

NCT ID: NCT05041972 Withdrawn - Clinical trials for HER2 Mutation-Related Tumors

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

A Global Phase 2 Study to Evaluate the Efficacy and Safety of ARX788 for Selected HER2-mutated or HER2-amplified/overexpressed Solid Tumors (ACE-Pan tumor-02)

NCT ID: NCT05039931 Withdrawn - Breast Cancer Clinical Trials

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.